Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

WellmarkerBio receives approval for Phase I clinical trial from the Australian Therapeutic Goods Administration

prnasiaMarch 04, 2021

Tag: Wellmarker , Australian , TGA , WM-S1-030 , Erbitux

PharmaSources Customer Service